Chemotherapeutic potential of phosphodiesterase inhibitors.

[1]  J. Beavo,et al.  Identification and Characterization of a Novel Family of Cyclic Nucleotide Phosphodiesterases* , 1998, The Journal of Biological Chemistry.

[2]  James F. Smith,et al.  Isolation and Characterization of PDE9A, a Novel Human cGMP-specific Phosphodiesterase* , 1998, The Journal of Biological Chemistry.

[3]  J. Cheng,et al.  Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. , 1998, Biochemical and biophysical research communications.

[4]  J. Corbin,et al.  Hydropathic analysis and mutagenesis of the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). cGMP versus cAMP substrate selectivity. , 1998, Biochemistry.

[5]  J. Corbin,et al.  Potential Roles of Conserved Amino Acids in the Catalytic Domain of the cGMP-binding cGMP-specific Phosphodiesterase (PDE5)* , 1998, The Journal of Biological Chemistry.

[6]  S. Katz,et al.  Calcium Sensitising Agents in Heart Failure , 1998, Drugs & aging.

[7]  T. Torphy.  Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. , 1998, American journal of respiratory and critical care medicine.

[8]  J. Corbin,et al.  Binding of cGMP to both allosteric sites of cGMP-binding cGMP-specific phosphodiesterase (PDE5) is required for its phosphorylation. , 1998, The Biochemical journal.

[9]  R. Colman,et al.  Cyclic AMP phosphodiesterases in human lymphocytes , 1997, British journal of haematology.

[10]  W. Rocque,et al.  Human recombinant phosphodiesterase 4B2B binds (R)-rolipram at a single site with two affinities. , 1997, Biochemistry.

[11]  J. Karlsson,et al.  Phosphodiesterase 4 inhibitors for the treatment of asthma , 1997 .

[12]  R. Owens,et al.  Human phosphodiesterase 4A: characterization of full-length and truncated enzymes expressed in COS cells. , 1997, The Biochemical journal.

[13]  T. Michaeli,et al.  Alternative Splicing of the High Affinity cAMP-Specific Phosphodiesterase (PDE7A) mRNA in Human Skeletal Muscle and Heart* , 1997, The Journal of Biological Chemistry.

[14]  G. Angelini,et al.  Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. , 1997, British journal of urology.

[15]  G. Milligan,et al.  Tailoring cAMP-signalling responses through isoform multiplicity. , 1997, Trends in biochemical sciences.

[16]  M. Czarniecki,et al.  Inhibitors of PDE1 and PDE5 cGMP phosphodiesterases: patents and therapeutic potential , 1997 .

[17]  R. Fischmeister,et al.  cGMP-stimulated cyclic nucleotide phosphodiesterase regulates the basal calcium current in human atrial myocytes. , 1997, The Journal of clinical investigation.

[18]  K. Ferguson,et al.  Isolation and characterization of human cDNAs encoding a cGMP-stimulated 3',5'-cyclic nucleotide phosphodiesterase. , 1997, Gene.

[19]  J. Souness,et al.  Proposal for pharmacologically distinct conformers of PDE4 cyclic AMP phosphodiesterases. , 1997, Cellular signalling.

[20]  M. Teixeira,et al.  Phosphodiesterase (PDE)4 inhibitors: anti-inflammatory drugs of the future? , 1997, Trends in pharmacological sciences.

[21]  S. Holgate,et al.  The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. , 1997, The European respiratory journal.

[22]  R. Haslam,et al.  Activation of cGMP-stimulated phosphodiesterase by nitroprusside limits cAMP accumulation in human platelets: effects on platelet aggregation. , 1997, The Biochemical journal.

[23]  E. Degerman,et al.  Structure, Localization, and Regulation of cGMP-inhibited Phosphodiesterase (PDE3)* , 1997, The Journal of Biological Chemistry.

[24]  R. Owens,et al.  PDE 4 inhibitors: the use of molecular cloning in the design and development of novel drugs , 1997 .

[25]  O. Rampin,et al.  [The peripheral pharmacology of erection]. , 1997, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[26]  D. Tulshian,et al.  Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor. , 1996, Journal of cardiovascular pharmacology.

[27]  J. Beavo,et al.  Identification and tissue-specific expression of PDE7 phosphodiesterase splice variants. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[28]  T. Saeki,et al.  Section Review Cardiovascular & Renal: Phosphodiesterase 5 inhibitors in development for cardiovascular therapy , 1996 .

[29]  J. Beavo,et al.  Multiplicity within cyclic nucleotide phosphodiesterases. , 1996, Biochemical Society transactions.

[30]  J. Beavo,et al.  The Calmodulin-dependent Phosphodiesterase Gene PDE1C Encodes Several Functionally Different Splice Variants in a Tissue-specific Manner* , 1996, The Journal of Biological Chemistry.

[31]  S Jacobitz,et al.  Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding. , 1996, Molecular pharmacology.

[32]  J. Lubsen,et al.  Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial. , 1996, Heart.

[33]  Andrew Simon Bell,et al.  Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction , 1996 .

[34]  L. Wang,et al.  Characterization of two recombinant PDE3 (cGMP-inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 insect cells. , 1996, Biochemistry.

[35]  P. Barnes,et al.  Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T‐lymphocytes: role in regulating proliferation and the biosynthesis of interleukin‐2 , 1996, British journal of pharmacology.

[36]  W. Henderson,et al.  Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. , 1996, The Journal of investigative dermatology.

[37]  G. Muirhead,et al.  Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. , 1996, International journal of impotence research.

[38]  N. Dodic,et al.  Synthesis and cyclic GMP phosphodiesterase inhibitory activity of a series of 6-phenylpyrazolo[3,4-d]pyrimidones. , 1996, Journal of medicinal chemistry.

[39]  E. Pettipher,et al.  Regulation of tumour necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipram , 1996, British journal of pharmacology.

[40]  M. Houslay,et al.  Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram. , 1996, Cellular signalling.

[41]  A. Marfat,et al.  Biarylcarboxylic acids and -amides: inhibition of phosphodiesterase type IV versus [3H]rolipram binding activity and their relationship to emetic behavior in the ferret. , 1996, Journal of medicinal chemistry.

[42]  J. Beavo,et al.  Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. , 1995, Physiological reviews.

[43]  T. Podzuweit,et al.  Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine. , 1995, Cellular signalling.

[44]  A. Hatzelmann,et al.  PDE isoenzymes as targets for anti-asthma drugs. , 1995, The European respiratory journal.

[45]  G. Sybrecht,et al.  Effects of the mixed phosphodiesterase III/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstruction. , 1995, Respiratory medicine.

[46]  C. Demoliou-Mason.  Overview: Cardiovascular & Renal; Cyclic nucleotide phosphodiesterase inhibitors , 1995 .

[47]  T. Saeki,et al.  A selective type V phosphodiesterase inhibitor, E4021, dilates porcine large coronary artery. , 1995, The Journal of pharmacology and experimental therapeutics.

[48]  H. Kase,et al.  A new cyclic nucleotide phosphodiesterase isozyme expressed in the T-lymphocyte cell lines. , 1993, Biochemical and biophysical research communications.

[49]  P. Anderer,et al.  EEG Mapping and psychopharmacological studies with denbufylline in SDAT and MID , 1992, Biological Psychiatry.

[50]  D. DeMets,et al.  Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. , 1991, The New England journal of medicine.

[51]  N. Turner,et al.  Characterization of guinea-pig eosinophil phosphodiesterase activity. Assessment of its involvement in regulating superoxide generation. , 1991, Biochemical pharmacology.

[52]  J. Beavo,et al.  High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells. , 1991, The Journal of biological chemistry.

[53]  N. Geyer,et al.  Rolipram in Major Depressive Disorder: Results of a Double-Blind Comparative Study with Imipramine , 1989, Pharmacopsychiatry.

[54]  G. Némoz,et al.  Selective inhibition of one of the cyclic AMP phosphodiesterases from rat brain by the neurotropic compound rolipram. , 1985, Biochemical pharmacology.

[55]  J. Voorhees,et al.  Papaverine and Ro 20-1724 inhibit cyclic nucleotide phosphodiesterase activity and increase cyclic AMP levels in psoriatic epidermis in vitro. , 1978, The Journal of investigative dermatology.

[56]  Z. Huang,et al.  CDP840 , 2007, Cell Biochemistry and Biophysics.

[57]  V. Arshavsky,et al.  Photoreceptor phosphodiesterase: interaction of inhibitory gamma subunit and cyclic GMP with specific binding sites on catalytic subunits. , 1998, Methods.

[58]  S. Christensen,et al.  SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. , 1998, The Journal of pharmacology and experimental therapeutics.

[59]  W. K. Sonnenburg,et al.  Identification, quantitation, and cellular localization of PDE1 calmodulin-stimulated cyclic nucleotide phosphodiesterases. , 1998, Methods.

[60]  E. Degerman,et al.  Phosphorylation and activation of hormone-sensitive adipocyte phosphodiesterase type 3B. , 1998, Methods.

[61]  J. Polson,et al.  Cyclic nucleotide phosphodiesterases and vascular smooth muscle. , 1996, Annual review of pharmacology and toxicology.

[62]  M. N. Palfreyman,et al.  Phosphodiesterase type IV inhibitors. , 1996, Progress in medicinal chemistry.

[63]  E. Degerman,et al.  6 – cGMP-Inhibited Phosphodiesterases (PDE3) , 1996 .

[64]  J. Arnold,et al.  The role of phosphodiesterase inhibitors in heart failure. , 1993, Pharmacology & therapeutics.

[65]  K. Sakuma,et al.  Demonstration of functional compartments of cyclic AMP in rat platelets by the use of phosphodiesterase inhibitors. , 1992, Advances in second messenger and phosphoprotein research.

[66]  M. Matsuhashi.  [1] Acetyl-CoA carboxylase from yeast: EC 6.4.1.2 Acetyl-CoA: carbon-dioxide ligase (ADP) , 1969 .